Type 2 diabetes mellitus has become an enormous and worldwide healthcare problem that
is almost certain to worsen. Current therapies, which address glycemia and insulin …

Known treatments of type 2 diabetes mellitus have limitations such as weight gain, and
hypoglycaemias. A new perspective is the use of incretin hormones and incretin enhancers …

Background: Diabetes is a chronic disease that occurs when the pancreas does not produce
enough insulin, or when the body cannot effectively use the insulin it produces …

Insulin resistance and type 2 diabetes mellitus are associated with impaired postprandial
secretion of glucagon-like peptide-1 (GLP-1), a potent insulinotropic hormone. The direct …

Cholecystokinin (CCK) is a peptide hormone that is released from the gut in response to
nutrients such as lipids to lower food intake. Here we report that a primary increase of CCK …

MAN)—Incretin mimetics and inhibitors of the protease dipeptidyl peptidase (DPP)-4 are
new classes of antidiabetic agents first introduced in the years 2005 (exenatide) and 2007 …

OBJECTIVE Glucose-dependent insulinotropic polypeptide (GIP), unlike glucagon-like
peptide (GLP)-1, lacks glucose-lowering properties in patients with type 2 diabetes. We …

Aims: Albiglutide is a glucagon‐like peptide‐1 (GLP‐1) mimetic generated by genetic fusion
of a dipeptidyl peptidase‐IV‐resistant GLP‐1 dimer to human albumin. Albiglutide was …

Aims: The study evaluated the efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor,
vildagliptin, and metformin in drug‐naïve elderly patients with type 2 diabetes. The primary …

Objective: Glucagon-like peptide-1 (GLP-1) is insulinotropic, but its effect on the α-cell is less
clear. We investigated the dose-response relationship for GLP-1-induced glucagon …